Literature DB >> 9731026

Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension.

F T Kaneko1, A C Arroliga, R A Dweik, S A Comhair, D Laskowski, R Oppedisano, M J Thomassen, S C Erzurum.   

Abstract

Primary pulmonary hypertension (PPH) is a rare and fatal disease of unknown etiology. Inflammatory oxidant mechanisms and deficiency in nitric oxide (NO) have been implicated in the pathogenesis of pulmonary hypertension. In order to investigate abnormalities in oxidants and antioxidants in PPH, we studied intrapulmonary NO levels, biochemical reaction products of NO, and antioxidants (glutathione [GSH], glutathione peroxidase [GPx], and superoxide dismutase [SOD]) in patients with PPH (n = 8) and healthy controls (n = 8). Intrapulmonary gases and fluids were sampled at bronchoscopy. Pulmonary hypertension was determined by right-heart catheterization. NO and biochemical reaction products of NO in the lung were decreased in PPH patients in comparison with healthy controls (NO [ppb] in airway gases: control, 8 +/- 1; PPH, 2.8 +/- 0. 9; p = 0.016; and NO products [microM] in bronchoalveolar lavage fluid [BALF]: control, 3.3 +/- 1.05; PPH, 0.69 +/- 0.21; p = 0.03). However, GSH in the lungs of PPH patients was higher than in those of controls (GSH [microM] in BALF: 0.55 +/- 0.04; PPH, 0.9 +/- 0.1; p = 0.015). SOD and GPx activities were similar in the two groups (p >/= 0.50). Biochemical reaction products of NO were inversely correlated with pulmonary artery pressures (R = -0.713; p = 0.047) and with years since diagnosis of PPH (R = -0.776; p = 0.023). NO reaction products are formed through interactions between oxidants and NO, with the end products of reaction dependent upon the relative levels of the two types of molecules. The findings of the study therefore show that NO and oxidant reactions in the lung are related to the increased pulmonary artery pressures in PPH.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9731026     DOI: 10.1164/ajrccm.158.3.9802066

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  73 in total

Review 1.  Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.

Authors:  Marjorie Barrier; Jolyane Meloche; Maria Helena Jacob; Audrey Courboulin; Steeve Provencher; Sébastien Bonnet
Journal:  Cell Mol Life Sci       Date:  2012-03-25       Impact factor: 9.261

2.  Oxidative stress in patients with COPD and pulmonary hypertension.

Authors:  Pavol Joppa; Darina Petrásová; Branislav Stancák; Zuzana Dorková; Ruzena Tkácová
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

3.  Alterations of cellular bioenergetics in pulmonary artery endothelial cells.

Authors:  Weiling Xu; Thomas Koeck; Abigail R Lara; Donald Neumann; Frank P DiFilippo; Michelle Koo; Allison J Janocha; Fares A Masri; Alejandro C Arroliga; Constance Jennings; Raed A Dweik; Rubin M Tuder; Dennis J Stuehr; Serpil C Erzurum
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-16       Impact factor: 11.205

4.  Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).

Authors:  Reiner Frey; Corina Becker; Sigrun Unger; Anja Schmidt; Georg Wensing; Wolfgang Mück
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

5.  High levels of zinc-protoporphyrin identify iron metabolic abnormalities in pulmonary arterial hypertension.

Authors:  Ilka Decker; Sudakshina Ghosh; Suzy A Comhair; Samar Farha; Wai Hong Wilson Tang; Margaret Park; Sihe Wang; Alan E Lichtin; Serpil C Erzurum
Journal:  Clin Transl Sci       Date:  2011-08       Impact factor: 4.689

6.  Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis.

Authors:  A Tabarroki; D J Lindner; V Visconte; L Zhang; H J Rogers; Y Parker; H K Duong; A Lichtin; M E Kalaycio; M A Sekeres; S E Mountantonakis; G A Heresi; R V Tiu
Journal:  Leukemia       Date:  2014-01-10       Impact factor: 11.528

Review 7.  Matricellular protein thrombospondin-1 in pulmonary hypertension: multiple pathways to disease.

Authors:  Natasha M Rogers; Kedar Ghimire; Maria J Calzada; Jeffrey S Isenberg
Journal:  Cardiovasc Res       Date:  2017-07-01       Impact factor: 10.787

8.  An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications.

Authors:  Raed A Dweik; Peter B Boggs; Serpil C Erzurum; Charles G Irvin; Margaret W Leigh; Jon O Lundberg; Anna-Carin Olin; Alan L Plummer; D Robin Taylor
Journal:  Am J Respir Crit Care Med       Date:  2011-09-01       Impact factor: 21.405

9.  Breath analysis in pulmonary arterial hypertension.

Authors:  Frank S Cikach; Adriano R Tonelli; Jarrod Barnes; Kelly Paschke; Jennie Newman; David Grove; Luma Dababneh; Sihe Wang; Raed A Dweik
Journal:  Chest       Date:  2014-03-01       Impact factor: 9.410

10.  Inhibition of p38 MAPK reverses hypoxia-induced pulmonary artery endothelial dysfunction.

Authors:  Roshan P Weerackody; David J Welsh; Roger M Wadsworth; Andrew J Peacock
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-02-06       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.